Breaking News Instant updates and real-time market news.

BXC

BlueLinx

$40.73 /

-1.53 (-3.62%)

16:25
07/22/21
07/22
16:25
07/22/21
16:25

BlueLinx initiated with a Hold at Loop Capital

Loop Capital initiated coverage of BlueLinx with a Hold rating and $45 price target.

  • 04

    Aug

BXC BlueLinx
$40.73 /

-1.53 (-3.62%)

05/06/21 Craig-Hallum
BlueLinx price target raised to $85 from $65 at Craig-Hallum
03/10/21
BlueLinx participates in a conference call with Benchmark
02/12/21
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Hot Stocks
BAE Systems receives concept development contract for OMFV program » 18:19
07/23/21
07/23
18:19
07/23/21
18:19
BAESY

BAE Systems

$30.51 /

+0.38 (+1.26%)

The U.S. Army has awarded…

The U.S. Army has awarded BAE Systems, Inc. a contract for the concept development phase of the Optionally Manned Fighting Vehicle program. During this phase, BAE Systems will further develop a design that will meet - with ample growth and adaptability - the Army's needs for lethality, mobility and survivability on future battlefields. BAE Systems, along with teammate Elbit Systems of America, will explore crew automation, active protection, and other transformational combat vehicle technologies and turret solutions that will deliver the advanced warfighting capabilities the Army needs for the future.

ShowHide Related Items >><<
BAESY BAE Systems
$30.51 /

+0.38 (+1.26%)

BAESY BAE Systems
$30.51 /

+0.38 (+1.26%)

07/15/21 UBS
BAE Systems price target raised to 565 GBp from 516 GBp at UBS
05/25/21 Societe Generale
BAE Systems price target raised to 614 GBp from 606 GBp at Societe Generale
04/14/21 Morgan Stanley
BAE Systems price target lowered to 640 GBp from 647 GBp at Morgan Stanley
04/09/21 Exane BNP Paribas
BAE Systems downgraded to Neutral from Outperform at Exane BNP Paribas
BAESY BAE Systems
$30.51 /

+0.38 (+1.26%)

Hot Stocks
Gores Holdings V announces planned transfer of listing to NYSE » 18:07
07/23/21
07/23
18:07
07/23/21
18:07
GRSV

Gores Holdings V

$9.98 /

-0.03 (-0.30%)

, AMBP

Ardagh Metal Beverage

/

+

Gores Holdings V…

Gores Holdings V announced that, as contemplated by its previously announced business combination with Ardagh Metal Packaging S.A. and the contemplated listing of AMPSA's shares and warrants on the New York Stock Exchange in connection with and subject to the closing of the Business Combination, it intends to voluntarily remove the listing of its shares of common stock, warrants and units from The Nasdaq Capital Market. As previously announced, the company expects AMPSA's shares and warrants to commence trading on the NYSE the day after the closing of the Business Combination under the symbols "AMBP" and "AMBPW," respectively. GRSV's Class A common stock, warrants and units will continue to trade on Nasdaq until the closing of the Business Combination. The decision to list AMPSA's shares and warrants on the NYSE was made as part of the Business Combination. At the closing of the Business Combination, GRSV will delist its units, shares of common stock and warrants from Nasdaq. The NYSE listing and Nasdaq delisting are subject to the closing of the Business Combination and fulfillment of all NYSE listing requirements.

ShowHide Related Items >><<
GRSV Gores Holdings V
$9.98 /

-0.03 (-0.30%)

GRSV Gores Holdings V
$9.98 /

-0.03 (-0.30%)

Periodicals
Intel CEO sees chip shortage stretching well into 2022, IGN says » 18:04
07/23/21
07/23
18:04
07/23/21
18:04
INTC

Intel

$53.00 /

-2.925 (-5.23%)

, MSFT

Microsoft

$289.60 /

+3.42 (+1.20%)

, SONY

Sony

$100.66 /

+1.16 (+1.17%)

, NVDA

Nvidia

$195.56 /

-0.43 (-0.22%)

Intel (INTC) CEO Pat…

Intel (INTC) CEO Pat Gelsinger said on the company's Q2 earnings call that he anticipates the recent chip shortage to continue well into 2022, with supply issues extending into 2023, IGN's Taylor Lyles reports. "While I expect the shortages to bottom out in the second half, it will take another one to two years before the industry is able to completely catch up with the demand," Gelsinger said. The semiconductor shortage has caused supply strains across numerous industries, including gaming, as hardware such as the PlayStation 5 (SONY), Xbox Series X/S (MSFT), and RTX 30 graphics cards from Nvidia (NVDA) likely to continue experiencing supply issues, Lyles notes. Reference Link

ShowHide Related Items >><<
SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

07/23/21 Jefferies
Intel price target lowered to $52 from $54 at Jefferies
07/23/21 BMO Capital
Intel price target lowered to $70 from $75 at BMO Capital
07/23/21 Evercore ISI
Intel price target lowered to $60 from $75 at Evercore ISI
07/23/21 Truist
Intel price target lowered to $60 from $69 at Truist
MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

07/23/21 Barclays
Microsoft price target raised to $325 from $288 at Barclays
07/22/21 BofA
Microsoft price target raised to $325 from $305 at BofA
07/22/21 Cowen
Microsoft price target raised to $310 from $295 at Cowen
07/22/21 KeyBanc
Microsoft price target raised to $330 from $305 at KeyBanc
SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

07/23/21 Argus
Nvidia price target raised to $230 from $175 at Argus
07/22/21 Citi
Nvidia price target raised to $223 from $180 at Citi
07/21/21 Oppenheimer
Nvidia price target lowered to $235 from $925 at Oppenheimer
SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

NVDA Nvidia
$195.56 /

-0.43 (-0.22%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

INTC Intel
$53.00 /

-2.925 (-5.23%)

Hot Stocks
Pfizer awarded $1.35B Army contract modification for vaccine BNT162b2 production » 17:51
07/23/21
07/23
17:51
07/23/21
17:51
PFE

Pfizer

$41.69 /

+0.22 (+0.53%)

Pfizer was awarded a…

Pfizer was awarded a $1.35B modification to a contract for the production of vaccine BNT162b2. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 31, 2022. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital
07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

Hot Stocks
Clever Leaves to 'take advantage' of cannabis flower export approval in Colombia » 17:49
07/23/21
07/23
17:49
07/23/21
17:49
CLVR

Clever Leaves

$9.04 /

-0.21 (-2.27%)

Clever Leaves Holdings…

Clever Leaves Holdings hosted Colombian President Duque at its cultivation facility in Colombia for the signing of a new decree that allows Colombian licensed cannabis companies such as Clever Leaves to participate in the commercial production and export of medical cannabis flower. With flower representing an estimated 50% of the global medical cannabis markets, this decree doubles the total addressable market for Colombian cannabis producers. "Clever Leaves is well-positioned to take advantage of this opportunity to export dried cannabis flower, leveraging its 1.8 million sq. ft. CUMCS GACP certified cultivation facility, its EUGMP Part II certification covering the production of dry flower, and its 30-plus cannabinoid genetics registered in the country," the company said. "Colombia's environmental conditions, coupled with Clever Leaves' experience in sustainable cannabis growing, will allow the company to bring to market unique products with pharmaceutical quality. Colombian flower complements Clever Leaves' already strong Portuguese flower production, allowing the company to present a comprehensive portfolio, covering different strains and growing conditions, that will suit ever-evolving patient needs. Having shipped cannabis products to over 15 countries in five continents, Clever Leaves has a strong network of partners globally, who will benefit from its broader flower offering. Clever Leaves will leverage its position as a trusted B2B partner to develop and produce high quality and innovative products for medical cannabis patients around the world. This change in regulation, allowing for the export of dried flower, will catalyze the continued development of the Colombian medical cannabis industry by eliminating the restriction that blocked access to 50% of the global medical cannabis market. In addition, the decree includes features that will help Clever Leaves to drive additional growth, including streamlined processes in quota management systems, which enable efficiencies and improve Clever Leaves' ability to serve clients faster. The bill also includes access to medical cannabis for patients in Colombia."

ShowHide Related Items >><<
CLVR Clever Leaves
$9.04 /

-0.21 (-2.27%)

CLVR Clever Leaves
$9.04 /

-0.21 (-2.27%)

07/23/21 Cowen
Cowen starts 'show-me' story Clever Leaves at Market Perform
07/23/21 Cowen
Clever Leaves initiated with a Market Perform at Cowen
CLVR Clever Leaves
$9.04 /

-0.21 (-2.27%)

CLVR Clever Leaves
$9.04 /

-0.21 (-2.27%)

General news
Treasury Market Summary » 17:45
07/23/21
07/23
17:45
07/23/21
17:45
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: it was a profitable session for Wall Street's bulls on Friday, Bonds and stocks were mostly firm on the session, holding small gains into the close. Drivers on the day were the unexpected jump in jobless claims and the ECB's strengthening of its dovish guidance. Treasury yields richened with the longer dated rates falling over 3 bps, taking the 10-year down to 1.265% and the bond to 1.903% after the weaker data. Concurrently, Wall Street gave up some ground on the data. But, the ECB's tweak of its forward guidance, strengthening its dovish bent, helped underpin European bourses and bonds, with spillover to U.S. markets. The NASDAQ finished 0.36% firmer, with the S&P 500 0.2% higher, and the Dow up 0.07%. Other data included another record high level on the June leading index, and a bounce in existing home sales, accompanied by a record high sales price.

ShowHide Related Items >><<
$ECON Economic Data
/

+

Conference/Events
Alector to ho ld a conference call » 17:31
07/23/21
07/23
17:31
07/23/21
17:31
ALEC

Alector

$32.80 /

+1.1 (+3.47%)

Management reviews the…

Management reviews the AL001 Phase 2 results as discussed at the recently-held Alzheimer's International Conference on a conference call to be held on July 29 at 1 pm. Webcast Link

ShowHide Related Items >><<
ALEC Alector
$32.80 /

+1.1 (+3.47%)

ALEC Alector
$32.80 /

+1.1 (+3.47%)

07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
01/15/21 BofA
Alector reinstated with a Buy at BofA
ALEC Alector
$32.80 /

+1.1 (+3.47%)

ALEC Alector
$32.80 /

+1.1 (+3.47%)

Conference/Events
Ritchie Bros. to hold a virtual meeting » 17:25
07/23/21
07/23
17:25
07/23/21
17:25
RBA

Ritchie Bros.

$60.52 /

-0.11 (-0.18%)

Inside Edge Industry…

Inside Edge Industry Panel about the transportation industry covering OEM production delays, auction volumes & pricing, spot rate impact and driver shortages to be held on July 27 at 3 pm. Webcast Link

ShowHide Related Items >><<
RBA Ritchie Bros.
$60.52 /

-0.11 (-0.18%)

RBA Ritchie Bros.
$60.52 /

-0.11 (-0.18%)

05/12/21 National Bank
Ritchie Bros. downgraded to Sector Perform on valuation at National Bank
05/11/21 National Bank
Ritchie Bros. downgraded to Sector Perform from Outperform at National Bank
04/21/21 OTR Global
Ritchie Bros. downgraded to Mixed from Positive at OTR Global
02/24/21
Fly Intel: Top five analyst upgrades
RBA Ritchie Bros.
$60.52 /

-0.11 (-0.18%)

Syndicate
Synlogic files $250M mixed securities shelf  17:24
07/23/21
07/23
17:24
07/23/21
17:24
SYBX

Synlogic

$3.19 /

-0.05 (-1.54%)

 
ShowHide Related Items >><<
SYBX Synlogic
$3.19 /

-0.05 (-1.54%)

SYBX Synlogic
$3.19 /

-0.05 (-1.54%)

07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
SYBX Synlogic
$3.19 /

-0.05 (-1.54%)

  • 16
    Apr
SYBX Synlogic
$3.19 /

-0.05 (-1.54%)

Conference/Events
Infinity Pharmaceuticals to hold a KOL webinar » 17:14
07/23/21
07/23
17:14
07/23/21
17:14
INFI

Infinity Pharmaceuticals

$2.30 /

-0.24 (-9.47%)

Key Opinion Leader…

Key Opinion Leader Webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC clinical studies to be held on July 27 at 8 am. Webcast Link

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.30 /

-0.24 (-9.47%)

INFI Infinity Pharmaceuticals
$2.30 /

-0.24 (-9.47%)

07/07/21 B. Riley
Infinity Pharmaceuticals transferred with Buy, $7 target at B. Riley
03/23/21 B. Riley
Infinity Pharmaceuticals price target lowered to $7 from $8 at B. Riley
03/18/21 Truist
Infinity Pharmaceuticals initiated with a Buy at Truist
03/18/21 Truist
Infinity Pharmaceuticals initiated with a Buy at Truist
INFI Infinity Pharmaceuticals
$2.30 /

-0.24 (-9.47%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.30 /

-0.24 (-9.47%)

Syndicate
Beachbody Company files to sell 243.3M shares of common stock for holders  17:11
07/23/21
07/23
17:11
07/23/21
17:11
BODY

Beachbody Company

$10.83 /

+0.11 (+1.03%)

 
ShowHide Related Items >><<
BODY Beachbody Company
$10.83 /

+0.11 (+1.03%)

BODY Beachbody Company
$10.83 /

+0.11 (+1.03%)

07/08/21 Baird
Beachbody Company initiated with an Outperform at Baird
BODY Beachbody Company
$10.83 /

+0.11 (+1.03%)

BODY Beachbody Company
$10.83 /

+0.11 (+1.03%)

Hot Stocks
Tonix Pharmaceuticals trading resumes  17:10
07/23/21
07/23
17:10
07/23/21
17:10
TNXP

Tonix Pharmaceuticals

/

+

 
ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

Syndicate
Five Star Senior Living files $500M mixed securities shelf  17:08
07/23/21
07/23
17:08
07/23/21
17:08
FVE

Five Star Senior Living

$5.60 /

+0.1 (+1.82%)

 
ShowHide Related Items >><<
FVE Five Star Senior Living
$5.60 /

+0.1 (+1.82%)

FVE Five Star Senior Living
$5.60 /

+0.1 (+1.82%)

05/10/21 B. Riley
Five Star Senior Living price target raised to $8 from $7.50 at B. Riley
04/12/21 B. Riley
Five Star Senior Living price target lowered to $7.50 from $8.50 at B. Riley
12/10/20 Wells Fargo
Diversified Healthcare Trust downgraded to Underweight from Equal Weight at Wells Fargo
08/25/20
Fly Intel: Top five analyst initiations
FVE Five Star Senior Living
$5.60 /

+0.1 (+1.82%)

FVE Five Star Senior Living
$5.60 /

+0.1 (+1.82%)

Syndicate
Electric Last Mile Solutions files to sell 118.68M shares of common for holders  17:07
07/23/21
07/23
17:07
07/23/21
17:07
ELMS

Electric Last Mile Solutions

$9.10 /

-0.04 (-0.44%)

 
ShowHide Related Items >><<
ELMS Electric Last Mile Solutions
$9.10 /

-0.04 (-0.44%)

ELMS Electric Last Mile Solutions
$9.10 /

-0.04 (-0.44%)

07/20/21 Wedbush
Wedbush bullish on Electric Last Mile Solutions, initiates with an Outperform
07/20/21 Wedbush
Electric Last Mile Solutions initiated with an Outperform at Wedbush
07/08/21 Cowen
Electric Last Mile Solutions initiated with an Outperform at Cowen
ELMS Electric Last Mile Solutions
$9.10 /

-0.04 (-0.44%)

ELMS Electric Last Mile Solutions
$9.10 /

-0.04 (-0.44%)

Syndicate
Fortress Biotech files $125M mixed securities shelf  17:06
07/23/21
07/23
17:06
07/23/21
17:06
FBIO

Fortress Biotech

$3.07 /

-0.07 (-2.23%)

 
ShowHide Related Items >><<
FBIO Fortress Biotech
$3.07 /

-0.07 (-2.23%)

FBIO Fortress Biotech
$3.07 /

-0.07 (-2.23%)

06/17/21 B. Riley
Fortress Biotech price target lowered to $8 from $9 at B. Riley
04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
04/05/21 B. Riley
Fortress Biotech price target raised to $9 from $8 at B. Riley
02/17/21 Dawson James
Fortress Biotech price target raised to $21 from $16 at Dawson James
FBIO Fortress Biotech
$3.07 /

-0.07 (-2.23%)

FBIO Fortress Biotech
$3.07 /

-0.07 (-2.23%)

FBIO Fortress Biotech
$3.07 /

-0.07 (-2.23%)

Syndicate
LifeMD files to sell 1.5M shares of common stock for holders  17:05
07/23/21
07/23
17:05
07/23/21
17:05
LFMD

LifeMD

$10.04 /

-0.01 (-0.10%)

 
ShowHide Related Items >><<
LFMD LifeMD
$10.04 /

-0.01 (-0.10%)

LFMD LifeMD
$10.04 /

-0.01 (-0.10%)

07/19/21 BTIG
LifeMD price target lowered to $35 from $43 at BTIG
04/27/21 B. Riley
LifeMD 40% pullback brings 'opportunistic entry point,' says B. Riley
04/16/21 BTIG
LifeMD selloff brings buying opportunity, says BTIG
03/29/21 B. Riley
LifeMD revenue accelerating across brands, says B. Riley
LFMD LifeMD
$10.04 /

-0.01 (-0.10%)

LFMD LifeMD
$10.04 /

-0.01 (-0.10%)

LFMD LifeMD
$10.04 /

-0.01 (-0.10%)

Hot Stocks
AptarGroup signs pact to acquire majority stake in Voluntis at EUR8.70 per share » 17:04
07/23/21
07/23
17:04
07/23/21
17:04
ATR

AptarGroup

$136.12 /

+1.415 (+1.05%)

AptarGroup announced that…

AptarGroup announced that following the entry into exclusive negotiations with Voluntis on June 21, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22 a share purchase agreement for the acquisition of a majority stake in Voluntis, representing approximately 64.6% of the share capital of Voluntis at a price of EUR 8.70 per share. The completion of the transfer of the block of shares is expected to occur before the end of the third quarter 2021 and is subject to customary conditions, notably the approval of the French Ministry of Economy under the foreign investment clearance regulations. After and subject to completion of this acquisition, Aptar will launch a mandatory cash tender offer to acquire Voluntis' remaining shares for the same price of EUR 8.70 per share. The Tender Offer would be filed with the French Markets Authority in the third quarter and will be subject to the regulatory clearance from the AMF. If the regulatory conditions are met upon completion of the Tender Offer, Aptar intends to implement a squeeze-out on the remaining outstanding shares of Voluntis. In accordance with applicable law, Voluntis' board of directors, in accordance with the recommendation of the ad hoc committee, appointed Advolis Orfis as independent expert on July 5 and will issue, notably on the basis of the independent expert's report opining on the financial terms of the Tender Offer and potential subsequent squeeze-out, a reasoned opinion on the Tender Offer and its consequences on Voluntis, its shareholders and employees.

ShowHide Related Items >><<
ATR AptarGroup
$136.12 /

+1.415 (+1.05%)

ATR AptarGroup
$136.12 /

+1.415 (+1.05%)

04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
04/14/21 Baird
AptarGroup downgraded to Neutral at Baird
04/14/21 Baird
AptarGroup downgraded to Neutral from Outperform at Baird
01/20/21 Deutsche Bank
AptarGroup price target raised to $152 from $127 at Deutsche Bank
ATR AptarGroup
$136.12 /

+1.415 (+1.05%)

Hot Stocks
Rush Street Interactive launches online live dealer casino games in Michigan » 17:02
07/23/21
07/23
17:02
07/23/21
17:02
RSI

Rush Street Interactive

$9.71 /

-0.19 (-1.92%)

Rush Street Interactive…

Rush Street Interactive received authorization from the Michigan Gaming Control Board on the first day when the product was approved to launch online live dealer games in the state on its BetRivers.com website. Gaming enthusiasts in Michigan are now able to play an array of online table games from their mobile devices and computers on RSI's platform at BetRivers.com.

ShowHide Related Items >><<
RSI Rush Street Interactive
$9.71 /

-0.19 (-1.92%)

RSI Rush Street Interactive
$9.71 /

-0.19 (-1.92%)

05/14/21 Benchmark
Rush Street Interactive price target lowered to $25 from $34 at Benchmark
04/26/21 Needham
Rush Street Interactive initiated with a Buy at Needham
04/16/21
Fly Intel: Top five analyst initiations
04/16/21 Jefferies
Jefferies starts Rush Street Interactive at Buy with $21 price target
RSI Rush Street Interactive
$9.71 /

-0.19 (-1.92%)

RSI Rush Street Interactive
$9.71 /

-0.19 (-1.92%)

RSI Rush Street Interactive
$9.71 /

-0.19 (-1.92%)

Conference/Events
Prometheus to host virtual research and development day » 16:58
07/23/21
07/23
16:58
07/23/21
16:58
RXDX

Prometheus

$21.50 /

-0.9 (-4.02%)

Virtual Research and…

Virtual Research and Development Day to be held on July 28 at 9 am. Webcast Link

ShowHide Related Items >><<
RXDX Prometheus
$21.50 /

-0.9 (-4.02%)

RXDX Prometheus
$21.50 /

-0.9 (-4.02%)

04/26/21 Credit Suisse
Prometheus assumed with an Outperform at Credit Suisse
04/06/21 SVB Leerink
SVB Leerink bullish on Prometheus, initiates with an Outperform
04/06/21 Stifel
Prometheus initiated with a Buy at Stifel
04/06/21 Guggenheim
Prometheus initiated with a Buy at Guggenheim
RXDX Prometheus
$21.50 /

-0.9 (-4.02%)

  • 12
    Mar
RXDX Prometheus
$21.50 /

-0.9 (-4.02%)

Syndicate
Takung Art files to sell 571,429 shares of common stock for holders  16:55
07/23/21
07/23
16:55
07/23/21
16:55
TKAT

Takung Art

$5.93 /

-0.59 (-9.05%)

 
ShowHide Related Items >><<
TKAT Takung Art
$5.93 /

-0.59 (-9.05%)

Syndicate
Alset EHome files to sell 6.53M shares of common stock, pre-funded warrants » 16:52
07/23/21
07/23
16:52
07/23/21
16:52
AEI

Alset EHome

$4.88 /

-0.16 (-3.17%)

Aegis Capital is acting…

Aegis Capital is acting as manager of the offering.

ShowHide Related Items >><<
AEI Alset EHome
$4.88 /

-0.16 (-3.17%)

  • 11
    May
Conference/Events
Ensysce Biosciences to hold virtual investor day » 16:51
07/23/21
07/23
16:51
07/23/21
16:51
ENSC

Ensysce Biosciences

$6.61 /

-0.59 (-8.19%)

Virtual Investor Day to…

Virtual Investor Day to be held on July 27 at 11 am. Webcast Link

ShowHide Related Items >><<
ENSC Ensysce Biosciences
$6.61 /

-0.59 (-8.19%)

Hot Stocks
Tonix Pharmaceuticals to stop enrollment in Phase 3 RALLY study of TNX-102 SL » 16:41
07/23/21
07/23
16:41
07/23/21
16:41
TNXP

Tonix Pharmaceuticals

/

+

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding Corp. announced that the company has decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee of the RALLY study. Based on interim analysis results of the first 50% enrolled participants, the IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those treated with TNX-102 SL 5.6 mg and those receiving placebo. Tonix remains blinded to the detailed interim analysis results and only received the recommendation made by the IDMC. Preliminary blinded safety data from these participants did not reveal any new safety signals, and the decision to discontinue enrolling new participants is not related to safety. The company intends to continue studying those participants currently enrolled until completion and then proceed with a full analysis of the unblinded data, with the topline results expected to be reported in the fourth quarter of 2021, to determine the next steps in this program. "We are surprised and disappointed that the interim analysis did not support continued enrollment in this Phase 3 RALLY study, especially considering the previous Phase 3 RELIEF study, which had a similar design and achieved statistical significance on the primary endpoint. After the currently enrolled participants complete the study, we will proceed with a full analysis of the unblinded data from the study to determine the next steps in this program," commented Seth Lederman, M.D., President and Chief Executive Officer. "These results underscore the difficulty in managing and treating fibromyalgia. We thank the patients, caregivers and investigators who participated in the RALLY study."

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

Hot Stocks
Tonix Pharmaceuticals trading halted, news pending  16:40
07/23/21
07/23
16:40
07/23/21
16:40
TNXP

Tonix Pharmaceuticals

/

+

 
ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
/

+

TNXP Tonix Pharmaceuticals
/

+

Hot Stocks
FDA issues CRL saying it can't approve Incyte's retifanlimab BLA » 16:33
07/23/21
07/23
16:33
07/23/21
16:33
INCY

Incyte

$79.22 /

+0.635 (+0.81%)

Incyte Corporation…

Incyte Corporation announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding its Biologics License Application for retifanlimab, an intravenous PD-1 inhibitor, for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy. The complete response letter states that the FDA cannot approve the application in its present form. Consistent with the Oncologic Drugs Advisory Committee recommendation on June 24, 2021, the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the treatment of patients with advanced or metastatic SCAC. Incyte is reviewing the letter and will discuss next steps with the FDA. "Patients with SCAC who have progressed after first-line chemotherapy currently do not have approved treatment options," said Herve Hoppenot, Chief Executive Officer, Incyte. "While we are not surprised with the FDA decision given the ODAC recommendation, we are disappointed. We remain committed to advancing science to find solutions for patients with unmet medical needs, and we will ensure close coordination with the FDA in order to address feedback and determine next steps for the review of retifanlimab."

ShowHide Related Items >><<
INCY Incyte
$79.22 /

+0.635 (+0.81%)

INCY Incyte
$79.22 /

+0.635 (+0.81%)

07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
06/25/21 RBC Capital
Incyte price target lowered to $88 from $92 at RBC Capital
06/23/21 Benchmark
Incyte's retifanlimab does not seem likely to be approved, says Benchmark
02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
INCY Incyte
$79.22 /

+0.635 (+0.81%)

INCY Incyte
$79.22 /

+0.635 (+0.81%)

INCY Incyte
$79.22 /

+0.635 (+0.81%)

INCY Incyte
$79.22 /

+0.635 (+0.81%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.